HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 16, Pages 1649-1676
Publisher
Springer Science and Business Media LLC
Online
2020-08-29
DOI
10.1007/s40265-020-01379-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-associated hyperglycaemia in patients with HIV
- (2020) Mohammed Lamorde et al. Lancet HIV
- Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
- (2020) Anthony T. Podany et al. CLINICAL PHARMACOKINETICS
- Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial
- (2020) Kenneth Kintu et al. Lancet HIV
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
- (2019) Jose I. Bernardino et al. PLoS One
- Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
- (2019) JM Llibre et al. HIV MEDICINE
- Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial
- (2019) Kelly E Dooley et al. CLINICAL INFECTIOUS DISEASES
- Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks
- (2019) Rima K. Acosta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors
- (2019) Christian Hoffmann et al. AIDS REVIEWS
- Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077
- (2019) Raphael J Landovitz et al. CLINICAL INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
- (2019) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) Hans-Jürgen Stellbrink et al. Lancet HIV
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) David A Wohl et al. Lancet HIV
- Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
- (2019) Michael Aboud et al. Lancet HIV
- Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a 2-Drug Antiretroviral Therapy for HIV-1 Infection
- (2019) Marta Boffito et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
- (2019) Thomas Theo Brehm et al. MEDICINE
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
- (2019) Catriona Waitt et al. PLOS MEDICINE
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- 2489. Adverse Events with Biktarvy: Post-Marketing Study
- (2019) Edwin Hayes et al. Open Forum Infectious Diseases
- Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection
- (2019) Pedro Cahn et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Adverse drug reactions to integrase strand transfer inhibitors
- (2018) Katherine J. Lepik et al. AIDS
- Dolutegravir and metformin
- (2018) Dario Cattaneo et al. AIDS
- Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
- (2018) Nikki Mulligan et al. AIDS
- Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
- (2018) Edwin DeJesus et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition
- (2018) Emilie R Elliot et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
- (2018) Ruben van der Galiën et al. CLINICAL PHARMACOKINETICS
- Monitoring anonymous HIV testing in Estonia from 2005 to 2015
- (2018) K Rüütel et al. HIV MEDICINE
- Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection
- (2018) Pedro Cahn et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
- (2018) David R Bakal et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals
- (2018) Andrew M. Hill et al. Current Opinion in HIV and AIDS
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
- (2018) Jeremiah D. Momper et al. AIDS
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2018) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
- (2018) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
- (2018) Dario Cattaneo et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
- (2018) Lise Cuzin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling
- (2018) Rajith K R Rajoli et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting
- (2018) Karen Jacobson et al. MEDICINE
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
- (2018) Raphael J. Landovitz et al. PLOS MEDICINE
- Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
- (2017) Anton Pozniak et al. HIV CLINICAL TRIALS
- Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
- (2017) Jose R. Arribas et al. HIV CLINICAL TRIALS
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Brief Report
- (2017) José R. Arribas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir-induced hyperglycaemia in a patient living with HIV
- (2017) Milena McLaughlin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tolerability of integrase inhibitors in a real-life setting
- (2017) Judit Peñafiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
- (2017) Pedro Cahn et al. Lancet HIV
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- First reported use of elvitegravir and cobicistat during pregnancy
- (2016) Stein Schalkwijk et al. AIDS
- Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
- (2016) Manuel Tsiang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
- (2016) C Hoffmann et al. HIV MEDICINE
- Integrase strand transfer inhibitor-associated diabetes mellitus: A case report
- (2016) Peter S Fong et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals
- (2016) Melissa Herrin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Brief Report
- (2016) David Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
- (2016) Alison J. Rodger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen
- (2016) Wan-Jung Tsai et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
- (2016) Anthony Mills et al. LANCET INFECTIOUS DISEASES
- Antiretroviral Therapy for the Prevention of HIV-1 Transmission
- (2016) Myron S. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Change After Antiretroviral Therapy and Mortality
- (2015) B. Yuh et al. CLINICAL INFECTIOUS DISEASES
- Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
- (2015) Maren I. Blonk et al. CLINICAL INFECTIOUS DISEASES
- Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
- (2015) Walter Dehority et al. DRUGS
- Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
- (2015) AC Achhra et al. HIV MEDICINE
- Brief Report
- (2015) Sharon Walmsley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model
- (2015) Stein Schalkwijk et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
- (2015) Gary David Bowers et al. XENOBIOTICA
- Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients
- (2015) Leonardo Calza et al. Infectious Diseases
- Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
- (2015) Jean-Michel Molina et al. Lancet HIV
- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
- (2014) Jeffrey L. Lennox et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
- (2014) J. M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals
- (2014) Shelley A. McCormack et al. CLINICAL PHARMACOKINETICS
- Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data
- (2014) A. Mills et al. HIV CLINICAL TRIALS
- Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients
- (2014) L. Curtis et al. HIV CLINICAL TRIALS
- Raltegravir Pharmacokinetics During Pregnancy
- (2014) D. Heather Watts et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
- (2014) Eve-Irene Lepist et al. KIDNEY INTERNATIONAL
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
- (2014) Jose R Arribas et al. LANCET INFECTIOUS DISEASES
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
- (2014) Anton Pozniak et al. LANCET INFECTIOUS DISEASES
- Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- (2014) Beatriz Grinsztejn et al. LANCET INFECTIOUS DISEASES
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
- (2013) W. Spreen et al. HIV CLINICAL TRIALS
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
- (2013) B. Hernandez-Novoa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
- (2013) Hasina Samji et al. PLoS One
- Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study
- (2012) D. A. Wohl et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
- (2012) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults
- (2012) Frederick J. Lee et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
- (2012) Kelly E. Dooley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
- (2011) Alain Nguyen et al. AIDS
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Long-Term Safety from the Raltegravir Clinical Development Program
- (2011) Hedy Teppler et al. CURRENT HIV RESEARCH
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A case of rhabdomiolysis associated with raltegravir use
- (2010) Luca Dori et al. AIDS
- Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
- (2010) Esteban Martinez et al. AIDS
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
- (2010) F Croce et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution
- (2010) Mar Masiá et al. JOURNAL OF INFECTION
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Severe rhabdomyolysis associated with raltegravir use
- (2009) Teresa R Zembower et al. AIDS
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000???2006
- (2008) Claire L Townsend et al. AIDS
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination
- (2007) H. Jeong et al. XENOBIOTICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started